Multicenter Performance Study of QuadQuik Invitro Diagnostic Device

Not yet recruiting

• Conditions: HIV Infections; Syphilis Infection; Hepatitis C; Hepatitis B
• Interventions: Diagnostic Test: QuadQuik

• Registration Number: NCT05692505
• Lead Sponsor: Genlantis Diagnostics

Brief Summary

To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device

Detailed Description

Measurement Methodology Whole blood samples are collected by fingerstick. Samples tested immediately.

Using the supplied sample dropper, transfer specimen blood drop into the two sample wells. Wait 20-30 seconds. Add two drops of the supplied assay buffer (\~90µL) to the same sample wells Read result in 20 mins.

Primary end points will determine how accurate these tests are (p\<=0.02) by analyzing for:

Diagnostic Sensitivity; TP / (TP + FN) The ability of the test to correctly identify those patients with the disease Diagnostic Specificity; TN / (TN + FP) The ability of the test to correctly identify those patients who are truly free of the specific disease Positive Predictive Value: TP / (TP+ FP) The probability that subjects with a positive test truly have the disease. Negative Predictive Value: TN / (FN + TN) The probability that subjects with a negative test truly don't have the disease.

An estimated 200 patients are to be enrolled as follows:

150 with a documented medical history of HIV, HBV, HCV or Syphilis. A combination of 2 or 3 conditions is acceptable.

HbsAg patients need to have a HbsAg on file \< 2 years. HIV and HCV or Syphilis patients only need one antibody test in their medical chart.

50 with no documented medical history of HIV, HBV, HCV or Syphilis and are considered normal.

Male or female subjects, ages ≥18 years.

Study Timeline

• Status Verified: 2023-01
• Study First Submitted: 2023-01-11
• Study First Submitted QC: 2023-01-11
• Last Update Submitted: 2023-01-11
• Study First Posted: 2023-01-20
• Last Update Posted: 2023-01-20
• Study Start: 2023-04-01
• Primary Completion: 2023-04-01
• Study Completion: 2023-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

a documented medical history of HIV, HBV, HCV or syphilis. A combination of 2 or 3 conditions is acceptable.

HbsAg patients need to have a HbsAg on file < 2 years. HIV and HCV patients only need one antibody test in their medical chart. no documented medical history of HIV, HBV, HCV or syphilis and are considered normal.

Male or female subjects, ages ≥18 years. Signed informed consent provided by an authorized subject representative (based on local Institutional Review Board (IRB)/ethics panel requirements).-

Exclusion Criteria

Any other condition or prior therapy, which, in the opinion of the investigator, would make the subject unsuitable for this study.

Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days before randomization.-

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control subjects	QuadQuik	Subjects having no previous positive tests verified by certified laboratory
Positive test subjects	QuadQuik	Subjects having previous positive tests verified by certified laboratory

Primary Outcome Measures

Name	Time	Method
Standard performance criteria	<1 day	Diagnostic Sensitivity, Diagnostic Specificity, Positive Predictive Value, Negative Predictive Value

Trial Locations

Locations (1)

Genlantis Diagnostics; 🇺🇸 San Diego, California, United States